Core Viewpoint - The medical nebulizer industry is experiencing significant growth driven by the aging population and the increasing prevalence of chronic respiratory diseases, with the market size in China projected to reach 4.281 billion yuan by 2024, reflecting an 11.4% year-on-year increase [1][14]. Industry Overview - Medical nebulizers are devices that convert liquid medication into aerosol particles for inhalation, primarily used to treat various respiratory diseases [3]. - The main types of nebulizers include compressed air nebulizers, ultrasonic nebulizers, and mesh nebulizers, each with distinct mechanisms and applications [4][5]. Market Dynamics - The market for medical nebulizers is expected to grow due to the rising number of healthcare institutions, which reached 1,093,600 in China by the end of 2024, a 2.13% increase year-on-year [12]. - The production of medical nebulizers in China is also on the rise, with an expected output of 22.37 million units in 2024, marking a 12.6% increase [18]. Competitive Landscape - The market features numerous participants, including both international brands like Omron and Philips, and domestic companies such as Yuyue Medical and Haier Medical, which are enhancing their competitiveness through R&D and quality improvements [20]. Product Segmentation - Compressed nebulizers dominate the market with a 78% share due to their efficiency, while ultrasonic nebulizers hold a smaller share of 3%, and mesh nebulizers have gained traction with a 19% market share [16]. Regulatory Environment - The Chinese government is actively promoting the development of the medical nebulizer industry through various policies aimed at enhancing innovation and regulatory frameworks [7]. Future Trends - The industry is moving towards precision medication delivery, smart nebulizers for remote monitoring, and portable, eco-friendly designs to enhance user experience [26][27][28].

来源：金融界 主力资金净流出居前的分别为安必平（1174.99万元）、东富龙（1070.65万元）、安杰思（995.13万 元）、微电生理（983.9万元）、可孚医疗（916.41万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.71-0.031.07亿元7.18%2300003 乐普医疗17.276.931.07亿元5.73%3301363美好医疗20.037.175599.57万元11.04%4603987康德莱 9.235.734851.48万元12.43%5870199倍益康42.581.383949.32万元7.52%6002551尚荣医疗4.649.953736.73 万元22.93%7688068热景生物243.022.543614.97万元6.9%8688314康拓医疗40.08.113278.73万元 15.1%9688108赛诺医疗20.4420.022762.62万元19.98%10832278鹿得医疗12.484.962727.93万元13.05% 8月8日，医疗器械行业上涨0.93%，今日主力资金流出6.11亿元，成分股59只上涨，39只下跌。 ...

证券时报·数据宝统计显示，鹿得医疗所属的医药生物行业，目前整体涨幅为0.46%，行业内，目前股价 上涨的有344只，涨停的有赛诺医疗、创新医疗等5只。股价下跌的有138只，跌幅居前的有凯莱英、上 海谊众、安必平等，跌幅分别为7.72%、5.75%、4.92%。 两融数据显示，该股最新（8月7日）两融余额为918.59万元，其中，融资余额为918.59万元，近10日增 加239.05万元，环比增长35.18%。 鹿得医疗股价创出历史新高，截至10:31，该股上涨10.09%，股价报13.09元，成交量1021.02万股，成交 金额1.26亿元，换手率13.51%，该股最新A股总市值达23.04亿元，该股A股流通市值9.89亿元。 公司发布的一季报数据显示，一季度公司共实现营业收入6109.37万元，同比下降7.42%，实现净利润 633.43万元，同比增长62.89%，基本每股收益为0.0400元，加权平均净资产收益率1.57%。（数据宝） （文章来源：证券时报网） ...

证券代码：832278 证券简称：鹿得医疗 公告编号：2025-085 江苏鹿得医疗电子股份有限公司 关于减少注册资本通知债权人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、通知债权人的原由 江苏鹿得医疗电子股份有限公司（以下简称"公司"）于 2025 年 7 月 11 日 召开公司第四届董事会第九次会议，审议通过了《关于变更回购股份用途并注 销暨减少注册资本的议案》及《关于减少注册资本、取消监事会并修订<公司章 程>的议案》，上述议案已于 2025 年 7 月 29 日经公司 2025 年第一次临时股东会 审议通过。 根据《中华人民共和国公司法》《北京证券交易所上市公司持续监管指引第 4号——股份回购》等法律、法规及规范性文件的有关规定，鉴于公司目前暂无 实施员工持股计划及股权激励的具体计划，为提升股东价值，增加每股净资产 和每股股权对应的收益权益，增强投资者对公司的投资信心，维护广大投资者 的利益，公司拟对 2022年 9月完成回购的 1,500,000股股份进行注销，将导致公 司总股 ...

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300003 | 乐普医疗 | 6230.96万 | 5.49% | -1220.74万 | -1.08% | -5010.22万 | -4.42% | | 688656 | 浩欧博 | 3805.71万 | 13.20% | -1941.68万 | -6.74% | -1864.03万 | -6.47% | | 300238 | 冠昊生物 | 3491.91万 | 8.34% | 1570.15万 | 3.75% | -5062.06万 | -12.09% | | 300753 爱朋医疗 | | 3162.54万 | 5.27% | -998.81万 | -1.67% | -2163.72万 | -3.61% | | 300289 | 利德曼 | 3117.42万 | 27.46% | -1921.39万 | -16.93% | -1196.03万 | -10.54 ...

Group 1 - The stock price of Lude Medical closed at 11.59 yuan on July 29, 2025, down by 0.32 yuan, representing a decline of 2.69% from the previous trading day [1] - The trading volume for the day was 76,470 hands, with a total transaction amount of 90 million yuan [1] - Lude Medical operates in the medical device sector, focusing on the research, production, and sales of medical devices, including diagnostic and therapeutic equipment [1] Group 2 - On the evening of July 29, Lude Medical announced that its first extraordinary general meeting of shareholders in 2025 approved several proposals, including the adjustment of the purpose of share repurchase and the cancellation of shares, which will reduce registered capital [1]

（文章来源：证券日报） 证券日报网讯 7月29日晚间，鹿得医疗发布公告称，公司2025年第一次临时股东会审议通过了《关于变 更回购股份用途并注销暨减少注册资本的议案》等多项议案。 ...

江苏鹿得医疗电子股份有限公司 2025 年第一次临时股东会决议公告 证券代码：832278 证券简称：鹿得医疗 公告编号：2025-083 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 4.会议召集人：董事会 5.会议主持人：董事长项友亮 （一）会议召开情况 1.会议召开时间：2025 年 7 月 29 日 2.会议召开地点：南通工厂会议室 3.会议召开方式：现场投票、网络投票和其他投票相结合方式 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、高级管理人员出席或列席股东会情况 1.公司在任董事 9 人，出席 9 人； 2.公司董事会秘书出席会议； 本次临时股东会，公司其他高级管理人员、本公司聘请的见证律师均 列席参加。 二、议案审议情况 6.召开情况合法合规的说明： 本次股东会会议召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东会 ...

中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 关于江苏鹿得医疗电子股份有限公司 2025 年第一次临时股东会之法律意见书 致：江苏鹿得医疗电子股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受江苏鹿得医疗电子股份 有限公司（以下简称"公司"或"鹿得医疗"）的委托，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、《上市公 司股东会规则》（以下简称"《股东会规则》"）等法律、法规、规范性文件（以 下简称"法律、法规"）及《江苏鹿得医疗电子股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责 精神，就公司 2025 年第一次临时股东会（以下简称"本次股东会"）有关事宜出 具本法律意见书。 为出具本法律意见书之目的，本所律师对公司提供的与本次股东会有关的文 件和事实进行了核查和验证。在本所律师对公司提供的有关文件进行核查和验证 的过程中，本所假设： 1. 提供予本所 ...

Group 1: Market Performance - The average daily change for the North Exchange (北证) and A-shares (A股) shows significant fluctuations, with a peak of 30% for Tianrun Technology (天润科技) on July 25, 2025[8] - The trading volume for the North Exchange reached a total of 600 billion CNY, with an average turnover rate of 16% as of July 25, 2025[6] - The average price-to-earnings ratio (PE) for companies listed on the North Exchange varies significantly across industries, with some sectors showing a PE as high as 516.07[12] Group 2: Stock Performance - The top-performing stocks on July 25, 2025, include Tianrun Technology with a 30% increase and a market capitalization of 29.19 billion CNY[8] - Conversely, the worst-performing stock, Jikang Technology (基康技术), saw a decline of 12.56% with a market capitalization of 52.76 billion CNY[9] - The average daily change for the North Exchange was notably higher than that of the A-share market, indicating a more volatile trading environment[7] Group 3: Risks and Challenges - The report highlights risks including lower-than-expected policy support, insufficient technological innovation, and increased market competition[13] - Market volatility remains a significant concern, impacting investor sentiment and stock performance across various sectors[13]